Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer

Creative Commons License

Bisgin A., Kargi A., Yalcin A. D., Aydin C., Ekinci D., Savas B., ...More

BMC CANCER, vol.12, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 12
  • Publication Date: 2012
  • Doi Number: 10.1186/1471-2407-12-58
  • Journal Name: BMC CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Çukurova University Affiliated: No

Abstract

Background: Colorectal cancer is the third most common cancer and the third leading cause of cancer-related death. Bevacizumab is a humanized monoclonal antibody developed against vascular endothelial growth factor (VEGF) for the treatment of metastatic cancer. The parameters of RECIST (Response Evaluation Criteria for Solid Tumors) are not adequate to detect important treatment effects and response. Our goal was to evaluate the possibility of using sTRAIL (serum-soluble TNF-related apoptosis-inducing ligand) and VEGF as markers of treatment efficacy and prognosis in patients with metastatic colon cancer.